Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) EBT (2019 - 2025)

Historic EBT for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to -$111.1 million.

  • Madrigal Pharmaceuticals' EBT fell 388.35% to -$111.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$286.0 million, marking a year-over-year increase of 4485.68%. This contributed to the annual value of -$465.9 million for FY2024, which is 2469.34% down from last year.
  • Madrigal Pharmaceuticals' EBT amounted to -$111.1 million in Q3 2025, which was down 388.35% from -$42.2 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' 5-year EBT high stood at -$42.2 million for Q2 2025, and its period low was -$152.0 million during Q2 2024.
  • For the 5-year period, Madrigal Pharmaceuticals' EBT averaged around -$84.4 million, with its median value being -$76.9 million (2023).
  • In the last 5 years, Madrigal Pharmaceuticals' EBT crashed by 9187.08% in 2024 and then skyrocketed by 7220.59% in 2025.
  • Madrigal Pharmaceuticals' EBT (Quarter) stood at -$64.5 million in 2021, then tumbled by 33.08% to -$85.9 million in 2022, then crashed by 30.6% to -$112.2 million in 2023, then soared by 47.04% to -$59.4 million in 2024, then crashed by 87.02% to -$111.1 million in 2025.
  • Its EBT stands at -$111.1 million for Q3 2025, versus -$42.2 million for Q2 2025 and -$73.2 million for Q1 2025.